|
|
---
|
|
|
license: mit
|
|
|
---
|
|
|
|
|
|
# Dataset Description
|
|
|
|
|
|
|
|
|
## Dataset Summary
|
|
|
|
|
|
This dataset was derived from the Stanford HIV Genotype-Phenotype database and contains 1,733 HIV protease sequences. A
|
|
|
pproximately half of the sequences are resistant to at least one antiretroviral therapeutic (ART).
|
|
|
|
|
|
Supported Tasks and Leaderboards: None
|
|
|
|
|
|
Languages: English
|
|
|
|
|
|
## Dataset Structure
|
|
|
|
|
|
### Data Instances
|
|
|
Each column represents the protein amino acid sequence of the HIV protease protein. The ID field indicates the Genbank reference ID for future cross-referencing. There are 1,733 total protease sequences.
|
|
|
|
|
|
Data Fields: ID, sequence, fold, FPV, IDV, NFV, SQV
|
|
|
|
|
|
Data Splits: None
|
|
|
|
|
|
## Dataset Creation
|
|
|
|
|
|
Curation Rationale: This dataset was curated to train a model (HIV-BERT-PI) designed to predict whether an HIV protease sequence would result in resistance to certain antiretroviral (ART) drugs.
|
|
|
|
|
|
Initial Data Collection and Normalization: Dataset was downloaded and curated on 12/21/2021.
|
|
|
|
|
|
## Considerations for Using the Data
|
|
|
|
|
|
Social Impact of Dataset: Due to the tendency of HIV to mutate, drug resistance is a common issue when attempting to treat those infected with HIV.
|
|
|
Protease inhibitors are a class of drugs that HIV is known to develop resistance via mutations.
|
|
|
Thus, by providing a collection of protease sequences known to be resistant to one or more drugs, this dataset provides a significant collection of data that could be utilized to perform computational analysis of protease resistance mutations.
|
|
|
|
|
|
Discussion of Biases: Due to the sampling nature of this database, it is predominantly composed of subtype B sequences from North America and Europe with only minor contributions of Subtype C, A, and D.
|
|
|
Currently, there was no effort made to balance the performance across these classes.
|
|
|
As such, one should consider refinement with additional sequences to perform well on non-B sequences.
|
|
|
|
|
|
## Additional Information:
|
|
|
- Dataset Curators: Will Dampier
|
|
|
- Citation Information: TBA
|
|
|
|
|
|
|
|
|
|
